India, Aug. 11 -- image credit- shutterstock

Pfizer has announced the launch of its next-generation 20-valent pneumococcal conjugate vaccine (PCV20) for adults in India. With broader serotype coverage, Pfizer's vaccine marks a significant advancement in protection against pneumococcal disease in adults.

Pfizer's vaccine helps protect against clinically relevant 20 serotypes responsible for a majority of invasive and non-invasive pneumococcal disease. It enables timely and proactive protection for all adults, including those living with chronic conditions. PCV20 will be available as a single shot vaccine and those vaccinated with PCV20 may not need a second dose.

Meenakshi Nevatia, Managing Director, Pfizer Ltd., India, said, "We are ex...